 |
54 Diseases |  |
8 Trials |
|
8 Trials |  |
2662 News |  |
| «12...12131415161718192021222324» |
- ledipasvir/sofosbuvir / Generic mfg.
New trial: Extrahepatic Insulin Resistance in Chronic Hepatitis C (clinicaltrials.gov) - May 3, 2016
P=N/A, N=20, Recruiting, Sponsor: University Hospital, Geneva
- ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics (clinicaltrials.gov) - May 3, 2016
P4, N=30, Not yet recruiting, Sponsor: University of Nebraska
- New trial: Impact of Antiviral Therapy on Gastroesophageal Varices. (clinicaltrials.gov) - May 2, 2016
P=N/A, N=374, Active, not recruiting, Sponsor: Parc de Salut Mar
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting (clinicaltrials.gov) - Apr 28, 2016
P2, N=19, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed
- ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Enrollment change: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease (clinicaltrials.gov) - Apr 28, 2016
P2, N=10, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=25 --> 10
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Apr 21, 2016
P2, N=40, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | N=25 --> 10 Active, not recruiting --> Completed
- ||| ledipasvir/sofosbuvir / Generic mfg.
New trial, Adherence: Evaluation of HepCure Toolkit to Improve Harvoni Adherence (clinicaltrials.gov) - Apr 15, 2016
P=N/A, N=99, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- |||||||||| ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection (clinicaltrials.gov) - Apr 14, 2016
P3, N=225, Not yet recruiting, Sponsor: Gilead Sciences
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Enrollment open: Co-STARs: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (clinicaltrials.gov) - Apr 10, 2016
P3, N=240, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Trial primary completion date: HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection (clinicaltrials.gov) - Apr 7, 2016
P2, N=20, Active, not recruiting, Sponsor: HepNet Study House, German Liverfoundation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Aug 2016
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency (clinicaltrials.gov) - Apr 7, 2016
P2, N=35, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Aug 2016 Trial primary completion date: Jul 2016 --> Dec 2016
- ledipasvir/sofosbuvir / Generic mfg.
Enrollment change, IO biomarker: Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs (clinicaltrials.gov) - Apr 6, 2016
P4, N=36, Recruiting, Sponsor: Rockefeller University
Trial primary completion date: Jul 2016 --> Dec 2016 N=24 --> 36
- |||| ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Apr 4, 2016
P3, N=360, Active, not recruiting, Sponsor: Gilead Sciences
N=24 --> 36 Trial primary completion date: Feb 2017 --> Jul 2017
- ledipasvir/sofosbuvir / Generic mfg.
Phase classification, Trial initiation date, Trial primary completion date: LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients (clinicaltrials.gov) - Mar 29, 2016
P4, N=230, Not yet recruiting, Sponsor: Medical University of South Carolina
Trial primary completion date: Feb 2017 --> Jul 2017 Phase classification: P3 --> P4 | Initiation date: Feb 2016 --> Jun 2016 | Trial primary completion date: Feb 2017 --> Jun 2017
- ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study (clinicaltrials.gov) - Mar 24, 2016
P4, N=21, Recruiting, Sponsor: University of Texas Southwestern Medical Center
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial initiation date: CTN289: HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (clinicaltrials.gov) - Mar 18, 2016
P3, N=25, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
Phase classification: P3 --> P4 | Initiation date: Feb 2016 --> Jun 2016 | Trial primary completion date: Feb 2017 --> Jun 2017 Initiation date: Jan 2016 --> Apr 2016
- ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD) (clinicaltrials.gov) - Mar 16, 2016
P=N/A, N=24, Recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Jan 2016 --> Apr 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
New P3 trial: Co-STARs: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (clinicaltrials.gov) - Mar 14, 2016
P3, N=240, Not yet recruiting, Sponsor: Gilead Sciences
- ||| Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Clinical: Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) (clinicaltrials.gov) - Mar 14, 2016
P2, N=125, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: SL50: Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 (clinicaltrials.gov) - Mar 10, 2016
P3, N=50, Not yet recruiting, Sponsor: Tehran University of Medical Sciences
- Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma, Exviera (dasabuvir) / AbbVie
Trial primary completion date: DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (clinicaltrials.gov) - Mar 1, 2016
P2/3, N=32, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Jun 2016
- Daklinza (daclatasvir) / BMS
Trial primary completion date: Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients (clinicaltrials.gov) - Mar 1, 2016
P4, N=120, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
Trial completion: Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Mar 1, 2016
P2, N=18, Completed, Sponsor: Humanity & Healthy GI and Liver Centre
Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Completed
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Enrollment change: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting (clinicaltrials.gov) - Feb 26, 2016
P2, N=19, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Completed Recruiting --> Active, not recruiting | N=25 --> 19
- | ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease (clinicaltrials.gov) - Feb 25, 2016
P4, N=40, Not yet recruiting, Sponsor: Peter J. Ruane, M.D., Inc.
- ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection (clinicaltrials.gov) - Feb 24, 2016
P2, N=20, Completed, Sponsor: Peter J. Ruane, M.D., Inc.
Recruiting --> Active, not recruiting | N=25 --> 19 Active, not recruiting --> Completed
- | ledipasvir/sofosbuvir / Generic mfg.
New P1 trial: Study of Hepatitis C Treatment During Pregnancy (clinicaltrials.gov) - Feb 17, 2016
P1, N=15, Not yet recruiting, Sponsor: University of Pittsburgh
- ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir (clinicaltrials.gov) - Feb 3, 2016
P=N/A, N=15, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ribavirin / Generic mfg.
Enrollment open: 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF (clinicaltrials.gov) - Feb 1, 2016
P2, N=40, Recruiting, Sponsor: AIDS Clinical Trials Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection (clinicaltrials.gov) - Jan 25, 2016
P2, N=26, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: CTN289: HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (clinicaltrials.gov) - Jan 21, 2016
P3, N=25, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- sofosbuvir/velpatasvir / Generic mfg., daclatasvir/sofosbuvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New trial: REDEMPTION: Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods (clinicaltrials.gov) - Jan 19, 2016
P=N/A, N=10000, Enrolling by invitation, Sponsor: FixHepC
- |||| Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Clinical: Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) (clinicaltrials.gov) - Jan 15, 2016
P2, N=125, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection (clinicaltrials.gov) - Jan 15, 2016
P2, N=111, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection (clinicaltrials.gov) - Dec 29, 2015
P3, N=100, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy (clinicaltrials.gov) - Dec 23, 2015
P4, N=40, Recruiting, Sponsor: Wilhelminenspital Vienna
- || ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients (clinicaltrials.gov) - Dec 16, 2015
P3, N=230, Not yet recruiting, Sponsor: Medical University of South Carolina
- |||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Ledipasvir/Sofosbuvir Fixed-Dose Combination (clinicaltrials.gov) - Dec 14, 2015
P2, N=100, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment change: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection (clinicaltrials.gov) - Dec 11, 2015
P3, N=280, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed N=200 --> 280
- ||| Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Sovaldi (sofosbuvir) / Gilead
Enrollment open: A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials (clinicaltrials.gov) - Dec 11, 2015
P=N/A, N=500, Enrolling by invitation, Sponsor: Gilead Sciences
N=200 --> 280 Not yet recruiting --> Enrolling by invitation
- ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection (clinicaltrials.gov) - Dec 11, 2015
P2, N=68, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Completed
- ||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment open, Trial primary completion date: Use-Results Surveillance Study of Harvoni (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=3000, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2018 --> Jul 2018
- ||||||| ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection (clinicaltrials.gov) - Dec 10, 2015
P3, N=335, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2018 --> Jul 2018 Active, not recruiting --> Completed
- |||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies (clinicaltrials.gov) - Dec 6, 2015
P3, N=300, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment open, Trial initiation date: Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa (clinicaltrials.gov) - Dec 4, 2015
P2, N=120, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Nov 2015
- |||||||||| ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection (clinicaltrials.gov) - Nov 25, 2015
P3, N=100, Not yet recruiting, Sponsor: Gilead Sciences
- ribavirin / Generic mfg.
New P2 trial: 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF (clinicaltrials.gov) - Nov 16, 2015
P2, N=40, Not yet recruiting, Sponsor: AIDS Clinical Trials Group
- ||||| Zepatier (grazoprevir/elbasvir) / Merck (MSD)
New P2 trial: Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) (clinicaltrials.gov) - Nov 11, 2015
P2, N=125, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection (clinicaltrials.gov) - Nov 9, 2015
P3, N=153, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Nov 2015 Recruiting --> Active, not recruiting
- |||||||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies (clinicaltrials.gov) - Nov 9, 2015
P3, N=300, Not yet recruiting, Sponsor: Gilead Sciences